Skip to main content

Advertisement

SpringerLink
Log in

Assessing the Impact of Heart Failure Therapeutics on Quality of Life and Functional Capacity

  • Heart Failure (J Fang, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Chronic heart failure (CHF) is an increasingly common disorder with major impact on morbidity and mortality. Goals of therapy include improving survival, attenuating progression of disease, improving functional capacity, and improving health-related quality of life (HRQL). Although there are multiple HRQL instruments that are psychometrically valid, concerns exist on the ability to reliably measure HRQL concepts. Nevertheless, there has been an emphasis on improving HRQL and thus novel therapies and clinical trials have included HRQL assessment routinely. Nonpharmacologic interventions have made a greater impact on HRQL, including the use of transcutaneous aortic valve replacement, left ventricular assist devices, and cardiac resynchronization devices. Pharmacologic therapies have resulted in modest improvements in HRQL and these improvements are often not clinically meaningful to the patient and not lasting beyond 6 months. As novel therapies are developed for CHF patients, researchers must: (a) identify mechanisms that may meaningfully improve HRQL, (b) develop better instruments to measure HRQL, and (c) target the right population with enough impairment in their sense of well-being to enable an intervention to work. The recent publication of the Food and Drug Administration Draft Guidance for Use of Patient-Reported Outcome measures in clinical trials has served as the foundation for more robust trial design using these HRQL measures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of outstanding importance

  1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–220.

    Article  PubMed  Google Scholar 

  2. Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 2001;87(4):413–9.

    Article  PubMed  CAS  Google Scholar 

  3. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9.

    Article  PubMed  CAS  Google Scholar 

  4. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.

    Article  PubMed  Google Scholar 

  5. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292(23):2874–9.

    Article  PubMed  CAS  Google Scholar 

  6. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346(24):1845–53.

    Article  PubMed  Google Scholar 

  7. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329–38.

    Article  PubMed  Google Scholar 

  8. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49.

    Article  PubMed  CAS  Google Scholar 

  9. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–57.

    Article  PubMed  CAS  Google Scholar 

  10. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant. 2001;20(9):1016–24.

    Article  PubMed  CAS  Google Scholar 

  11. Vaishnava P, Lewis EF. Assessment of quality of life in severe heart failure. Curr Heart Fail Rep. 2007;4(3):170–7.

    Article  PubMed  Google Scholar 

  12. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol. 1993;71(12):1106–7.

    Article  PubMed  CAS  Google Scholar 

  13. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245–55.

    Article  PubMed  CAS  Google Scholar 

  14. Spertus J, Peterson E, Conard MW, et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J. 2005;150(4):707–15.

    Article  PubMed  Google Scholar 

  15. Lewis EF, Pfeffer MA, Feng A, et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol. 2011;6(4):845–55.

    Article  PubMed  CAS  Google Scholar 

  16. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977–2016.

    Article  PubMed  Google Scholar 

  17. Khalid U, Deswal A. Review: in systolic heart failure, low-sodium diets increase mortality compared with normal-sodium diets. Ann Intern Med. 2013;158(4):JC7.

    Article  PubMed  Google Scholar 

  18. Hummel SL, Seymour EM, Brook RD, et al. Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension. 2012;60(5):1200–6. Limited data is available on impact of low sodium diet on outcomes in heart failure. Use of a DASH diet was associated with some improvements in exercise capacity (6-min walk) and health status (dyspnea). A more definitive study is required.

    Article  PubMed  CAS  Google Scholar 

  19. Albert NM, Nutter B, Forney J, Slifcak E, Tang WH. A randomized controlled pilot study of outcomes of strict allowance of fluid therapy in hyponatremic heart failure (SALT-HF). J Card Fail. 2013;19(1):1–9.

    Article  PubMed  Google Scholar 

  20. Bekelman DB, Dy SM, Becker DM, et al. Spiritual well-being and depression in patients with heart failure. J Gen Intern Med. 2007;22(4):470–7.

    Article  PubMed  Google Scholar 

  21. Westaby S, Banning A, Neil D, Poole-Wilson P, Frazier OH. Optimism derived from 7.5 years of continuous-flow circulatory support. J Thorac Cardiovasc Surg. 2010;139(3):e45–7.

    Article  PubMed  Google Scholar 

  22. Gorodeski EZ, Chu EC, Chow CH, Levy WC, Hsich E, Starling RC. Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee. Circ Heart Fail. 2010;3(6):706–14.

    Article  PubMed  Google Scholar 

  23. Ketchum ES, Moorman AJ, Fishbein DP, et al. Predictive value of the Seattle Heart Failure Model in patients undergoing left ventricular assist device placement. J Heart Lung Transplant. 2010;29(9):1021–5.

    Article  PubMed  Google Scholar 

  24. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116(14):1555–62.

    Article  PubMed  CAS  Google Scholar 

  25. Guazzi M, Vicenzi M, Arena R. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. Eur J Heart Fail. 2012;14(1):82–90.

    Article  PubMed  CAS  Google Scholar 

  26. Redfield MM, Chen HH, Borlaug BA, et al. Effect of Phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;1–10. This is one of the largest studies assessing treatment of secondary pulmonary hypertension in heart failure patients. Despite promising smaller studies, RELAX demonstrated no significant changes in quality of life or functional capacity (measured with cardiopulmonary exercise testing or 6-min walk) in patients randomized to sildenafil. More research is required and patient selection may influence changes in these outcomes.

  27. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999;353(9146):9–13.

    Google Scholar 

  28. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7.

    Google Scholar 

  29. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–8.

    Article  PubMed  CAS  Google Scholar 

  30. Gallanagh S, Castagno D, Wilson B, et al. Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II). Cardiovasc Drugs Ther. 2011;25(1):77–85.

    Article  PubMed  Google Scholar 

  31. Dobre D, van Jaarsveld CH, deJongste MJ, Haaijer Ruskamp FM, Ranchor AV. The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2007;16(2):152–9.

    Article  PubMed  CAS  Google Scholar 

  32. Lewis EF. Still at the drawing board: improving quality of life in heart failure. Circ Heart Fail. 2012;5(2):137–9.

    Article  PubMed  Google Scholar 

  33. O'Meara E, Lewis E, Granger C, et al. Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Eur J Heart Fail. 2005;7(4):650–6.

    Article  PubMed  Google Scholar 

  34. Rector TS, Carson PE, Anand IS, et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the Minnesota Living with Heart Failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail. 2012;5(2):217–25.

    Article  PubMed  CAS  Google Scholar 

  35. Havranek EP, Spertus JA, Masoudi FA, Jones PG, Rumsfeld JS. Predictors of the onset of depressive symptoms in patients with heart failure. J Am Coll Cardiol. 2004;44(12):2333–8.

    Article  PubMed  Google Scholar 

  36. Morgan AL, Masoudi FA, Havranek EP, et al. Difficulty taking medications, depression, and health status in heart failure patients. J Card Fail. 2006;12(1):54–60.

    Article  PubMed  Google Scholar 

  37. O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56(9):692–9.

    Article  PubMed  Google Scholar 

  38. Xiong GL, Fiuzat M, Kuchibhatla M, Krishnan R, O'Connor CM, Jiang W. Health status and depression remission in patients with chronic heart failure: patient-reported outcomes from the SADHART-CHF trial. Circ Heart Fail. 2012;5(6):688–92. Although depression is highly prevalent in heart failure patients, routine treatment of depression with sertraline did not influence quality of life or outcomes. However, patients who noted improved depressive symptoms noted dramatic improvements in quality of life over time. Strategies to identify and treat depression require further refinements.

    Article  PubMed  Google Scholar 

  39. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.

    Article  PubMed  CAS  Google Scholar 

  40. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.

    Article  PubMed  CAS  Google Scholar 

  41. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309(8):781–91. Aldosterone-receptor antagonist did not dramatically improve health status or functional status in patients with diastolic dysfunction. This patient population is heterogeneous and identification of patients with limitations due to heart disease may enable better targeting of those patients who will benefit from this therapy. A larger study, TOPCAT, will be completed later in 2013.

    Article  PubMed  CAS  Google Scholar 

  42. Phelan D, Thavendiranathan P, Collier P, Marwick TH. Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomized controlled trials. Heart. 2012;98(23):1693–700.

    Article  PubMed  CAS  Google Scholar 

  43. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet. 2010;376(9744):875–85. This novel therapy may show promise for improving patient-reported outcomes (with or without beta blockers). More studies are required.

    Article  PubMed  CAS  Google Scholar 

  44. Volterrani M, Cice G, Caminiti G, et al. Effect of carvedilol, ivabradine, or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol. 2011;151(2):218–24.

    Article  PubMed  Google Scholar 

  45. Swedberg K, Komajda M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59(22):1938–45.

    Article  PubMed  CAS  Google Scholar 

  46. Jessup M, Greenberg B, Mancini D, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2 + −ATPase in patients with advanced heart failure. Circulation. 2011;124(3):304–13. As the use of cell-based therapies are developed, careful attention to blinding will be required as we determine the impact of these novel interventions on functional capacity and quality of life.

    Article  PubMed  CAS  Google Scholar 

  47. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369–79.

    PubMed  CAS  Google Scholar 

  48. Chen S, Yin Y, Krucoff MW. Effect of cardiac resynchronization therapy and implantable cardioverter defibrillator on quality of life in patients with heart failure: a meta-analysis. Europace. 2012;14(11):1602–7.

    Article  PubMed  Google Scholar 

  49. Veazie PJ, Noyes K, Li Q, et al. Cardiac resynchronization and quality of life in patients with minimally symptomatic heart failure. J Am Coll Cardiol. 2012;60(19):1940–4. Although quality of life improved over a 2.4-year follow-up, the difference between cardiac resynchronization vs defibrillator alone was only modestly different. However, quality of life was not as impaired as traditional candidates for resynchronization.

    Article  PubMed  Google Scholar 

  50. Reynolds MR, Magnuson EA, Wang K, et al. Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). J Am Coll Cardiol. 2012;60(6):548–58. Transcatheter valve surgery may greatly influence quality of life and functional status without the same degree of morbidity related to the intervention. More work is required to determine the optimal patients and identify the likelihood for success and improved health status. Finally, a quality of life instrument should be developed specifically for this population.

    Article  PubMed  Google Scholar 

  51. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364(15):1395–406.

    Article  PubMed  CAS  Google Scholar 

  52. Grantham JA, Jones PG, Cannon L, Spertus JA. Quantifying the early health status benefits of successful chronic total occlusion recanalization: results from the FlowCardia's Approach to Chronic Total Occlusion Recanalization (FACTOR) Trial. Circ Cardiovasc Qual Outcomes. 2010;3(3):284–90.

    Article  PubMed  Google Scholar 

  53. Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359(7):677–87.

    Article  PubMed  CAS  Google Scholar 

  54. Mark DB, Knight JD, Velazquez EJ, et al. Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial. Am Heart J. 2009;157(5):837–44. e831–3.

    Google Scholar 

  55. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241–51.

    Article  PubMed  CAS  Google Scholar 

  56. Rogers JG, Aaronson KD, Boyle AJ, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol. 2010;55(17):1826–34.

    Article  PubMed  Google Scholar 

  57. Shamaskin AM, Rybarczyk BD, Wang E, et al. Older patients (age 65+) report better quality of life, psychological adjustment, and adherence than younger patients 5 years after heart transplant: a multisite study. J Heart Lung Transplant. 2012;31(5):478–84.

    Article  PubMed  Google Scholar 

  58. O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1439–50.

    Article  PubMed  Google Scholar 

  59. Flynn KE, Pina IL, Whellan DJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1451–9.

    Article  PubMed  CAS  Google Scholar 

  60. Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. Eur J Heart Fail. 2010;12(7):706–15.

    Article  PubMed  Google Scholar 

  61. Bhardwaj A, Rehman SU, Mohammed AA, et al. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Am Heart J. 2012;164(5):793–9. e791.

    Google Scholar 

  62. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. Lancet. 2011;377(9766):658–66.

    Article  PubMed  Google Scholar 

  63. Yeh GY, McCarthy EP, Wayne PM, et al. Tai chi exercise in patients with chronic heart failure: a randomized clinical trial. Arch Intern Med. 2011;171(8):750–7.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

Dr. Eldrin Lewis reported receiving grants from Novartis, Inc., Amgen, Inc., and Sanofi-Aventis.

Author information

Authors and Affiliations

  1. Center for Advanced Heart Disease, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA, 02115, USA

    Eldrin F. Lewis MD, MPH

Authors
  1. Eldrin F. Lewis MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eldrin F. Lewis MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lewis, E.F. Assessing the Impact of Heart Failure Therapeutics on Quality of Life and Functional Capacity. Curr Treat Options Cardio Med 15, 425–436 (2013). https://doi.org/10.1007/s11936-013-0249-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-013-0249-2

Keywords

Search

Navigation